Six-month interim report (Q2) 2023
August 24, 2023 01:30 ET
|
ALK Abello
Bemærk venligst, at rapporten udelukkende forefindes på engelsk ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by...
Six-month interim report (Q2) 2023
August 24, 2023 01:30 ET
|
ALK Abello
ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by 11% in Q2 2023, driven by 17% growth in tablet sales and...
Dato for offentliggørelse af delårsrapport for første halvår (Q2) 2023 for ALK og webcast
August 18, 2023 06:45 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for første halvår (Q2) 2023 torsdag den 24. august 2023. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for investorer og...
Release date of six-month interim report (Q2) 2023 for ALK and audio cast
August 18, 2023 06:45 ET
|
ALK Abello
On Thursday, 24 August 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its six-month interim report (Q2) 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm...
Administrerende direktør Carsten Hellmann fratræder ved udgangen af 2023. Peter Halling udpeget som hans efterfølger
June 19, 2023 02:40 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) meddeler i dag, at Carsten Hellmann fratræder som administrerende direktør ved udgangen af 2023. Han efterfølges af Peter Halling senest den 1. januar 2024. ...
President & CEO Carsten Hellmann to step down end 2023. Peter Halling appointed as his successor
June 19, 2023 02:40 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that Carsten Hellman will step down as President & CEO at the end of 2023. He will be succeed by Peter Halling no later than 1 January 2024. The...
Stort, succesfuldt klinisk fase 3-studie når sit primære endemål og bekræfter potentialet af ALK's tabletvaccine mod husstøvmideallergi hos børn
June 08, 2023 10:27 ET
|
ALK Abello
Studiet mødte sit primære og alle væsentlige sekundære endemål med en forbedring i den totale kombinerede allergiske rhinitis-score (TCRS) på 22 % sammenlignet med placebo (primært endemål)....
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children
June 08, 2023 10:27 ET
|
ALK Abello
Primary and all key secondary confirmatory endpoints were met, with an improvement in the total combined allergic rhinitis score (TCRS) of 22% compared to placebo (primary endpoint). Results were...
Three-month interim report (Q1) 2023
May 09, 2023 01:20 ET
|
ALK Abello
Bemærk venligst, at rapporten udelukkende forefindes på engelsk. Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic...
Three-month interim report (Q1) 2023
May 09, 2023 01:20 ET
|
ALK Abello
Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic revenue growth in local currencies and increased operating profit...